MCID: PRS045
MIFTS: 48

Prostatic Hypertrophy

Categories: Reproductive diseases

Aliases & Classifications for Prostatic Hypertrophy

MalaCards integrated aliases for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 12 15 73
Benign Prostatic Hypertrophy 73
Prostatic Hyperplasia 73

Classifications:



External Ids:

Disease Ontology 12 DOID:11132

Summaries for Prostatic Hypertrophy

MalaCards based summary : Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to prostate disease and prostatic hyperplasia, benign, and has symptoms including prostatism An important gene associated with Prostatic Hypertrophy is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs Alfuzosin and Tamsulosin have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and heart, and related phenotypes are endocrine/exocrine gland and immune system

Related Diseases for Prostatic Hypertrophy

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Related Disease Score Top Affiliating Genes
1 prostate disease 29.8 KLK3 CYP19A1 AR
2 prostatic hyperplasia, benign 29.8 KLK3 AR ADRA1A
3 prostate cancer 10.4
4 male reproductive organ benign neoplasm 10.2 KLK3 CYP19A1
5 nodular prostate 10.2 KLK3 AR
6 postmenopausal atrophic vaginitis 10.2 ESR1 AR
7 vaginitis 10.2 ESR1 AR
8 androgen insensitivity, partial 10.2 CYP19A1 AR
9 bartholin's gland adenoma 10.2 PGR ESR1
10 vestibular gland benign neoplasm 10.2 PGR ESR1
11 vulvar syringoma 10.2 PGR ESR1
12 glassy cell carcinoma of the cervix 10.2 PGR ESR1
13 lung leiomyoma 10.2 PGR ESR1
14 vulvar leiomyoma 10.2 PGR ESR1
15 trigonitis 10.2 PGR ESR1
16 vulvar benign neoplasm 10.2 PGR ESR1
17 transsexualism 10.2 CYP19A1 AR
18 predominantly cortical thymoma 10.2 PGR ESR1
19 breast scirrhous carcinoma 10.2 PGR ESR1
20 breast medullary carcinoma 10.2 PGR ESR1
21 bartholin's gland benign neoplasm 10.2 PGR ESR1
22 cribriform carcinoma 10.2 PGR ESR1
23 progesterone resistance 10.2 PGR ESR1
24 alopecia, androgenetic, 1 10.2 CYP19A1 AR
25 adenoid basal cell carcinoma 10.2 PGR ESR1
26 endometrial mucinous adenocarcinoma 10.2 PGR ESR1
27 synchronous bilateral breast carcinoma 10.2 PGR ESR1
28 deep angioma 10.2 PGR ESR1
29 benign metastasizing leiomyoma 10.2 PGR CYP19A1
30 endometrial disease 10.2 ESR1 CYP19A1
31 muscle hypertrophy 10.2
32 cervical carcinosarcoma 10.2 PGR ESR1
33 female reproductive endometrioid cancer 10.2 PGR ESR1
34 glycogen-rich clear cell breast carcinoma 10.2 PGR ESR1
35 intramuscular hemangioma 10.2 PGR ESR1
36 cervical clear cell adenocarcinoma 10.2 PGR ESR1
37 inflammatory breast carcinoma 10.2 PGR ESR1
38 retinitis pigmentosa 47 10.2 PGR ESR1
39 bartholin's gland disease 10.2 PGR AR
40 corneal abscess 10.2 PGR AR
41 adenosarcoma 10.2 PGR ESR1
42 retinitis pigmentosa 20 10.2 PGR ESR1
43 withdrawal disorder 10.2 KLK3 AR
44 complete androgen insensitivity syndrome 10.2 CYP19A1 AR
45 luminal breast carcinoma 10.2 PGR ESR1
46 endometrial stromal nodule 10.2 PGR CYP19A1
47 uterine corpus cancer 10.2 PGR ESR1
48 aromatase deficiency 10.2 ESR1 CYP19A1
49 papillary hidradenoma 10.2 PGR AR
50 thoracic benign neoplasm 10.1 PGR ESR1

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN): (show top 50) (show all 52)


Acute Cystitis Acute Kidney Failure
Anthracosis Asbestosis
Balanoposthitis Bladder Cancer
Bladder Disease Bladder Neck Obstruction
Chronic Kidney Failure Chronic Myocardial Ischemia
Cystitis Cystitis Cystica
Epididymo-Orchitis First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Hydronephrosis Infected Hydrocele
Interstitial Cystitis Ischemic Heart Disease
Kidney Disease Left Bundle Branch Hemiblock
Lipoma of Spermatic Cord Low Compliance Bladder
Nephrolithiasis, X-Linked Recessive, with Renal Failure Neurogenic Bladder
Parkinson Disease, Late-Onset Pelvic Varices
Penile Disease Peyronie's Disease
Pinta Disease Pneumoconiosis
Postinflammatory Pulmonary Fibrosis Prostate Calculus
Prostate Cancer Prostate Carcinoma in Situ
Prostate Disease Prostatitis
Prostatocystitis Renal Pelvis Carcinoma
Right Bundle Branch Block Silicosis
Spermatocele Ureter, Cancer of
Ureterolithiasis Urethral Benign Neoplasm
Urethral Calculus Urethral Stricture
Urethritis Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to Prostatic Hypertrophy

Symptoms & Phenotypes for Prostatic Hypertrophy

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

MGI Mouse Phenotypes related to Prostatic Hypertrophy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.8 AR CYP19A1 EGF ESR1 FGF8 PCNA
2 immune system MP:0005387 9.76 AR CYP19A1 EGF ESR1 FGF8 LGALS8
3 muscle MP:0005369 9.43 ADRA1A AR CYP19A1 ESR1 FGF8 PGR
4 reproductive system MP:0005389 9.17 AR CYP19A1 EGF ESR1 FGF8 PCNA

Drugs & Therapeutics for Prostatic Hypertrophy

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alfuzosin Approved, Investigational Phase 4,Phase 3,Not Applicable 81403-80-7 2092
2
Tamsulosin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 106133-20-4 129211
3 Mirabegron Approved Phase 4 223673-61-8
4
Silodosin Approved Phase 4 160970-54-7
5
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
6
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
7
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
8
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2 58-22-0 6013
9
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
10
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
11
Dihydrotachysterol Approved Phase 4 67-96-9 5281010 5311071
12
Dutasteride Approved, Investigational Phase 4,Phase 3,Not Applicable 164656-23-9 6918296 152945
13
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
14
Dihydrotestosterone Illicit, Investigational Phase 4 521-18-6 10635
15 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
16 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
17 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
18 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
20 Mitogens Phase 4,Not Applicable
21 Adrenergic beta-Agonists Phase 4
22 Adrenergic Agonists Phase 4,Not Applicable
23 Adrenergic beta-3 Receptor Agonists Phase 4
24 Cholinergic Agents Phase 4,Phase 3,Phase 2
25 Neuromuscular Blocking Agents Phase 4
26 Cholinergic Antagonists Phase 4,Phase 2,Phase 3
27 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
28 Anesthetics Phase 4,Not Applicable
29 Neuromuscular Agents Phase 4,Phase 3
30 Neuromuscular Nondepolarizing Agents Phase 4
31 Solifenacin succinate Phase 4 242478-38-2
32 Muscarinic Antagonists Phase 4,Phase 2,Phase 3
33 Testosterone 17 beta-cypionate Phase 4,Phase 2
34 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
36 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
37 Androgens Phase 4,Phase 3,Phase 2,Not Applicable
38 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
39 Anabolic Agents Phase 4,Phase 2
40 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Antineoplastic Agents, Hormonal Phase 4,Phase 2
42 Parasympatholytics Phase 4
43
Cetrorelix Approved, Investigational Phase 3 120287-85-6 16129715 25074887
44
Acetylcholine Approved Phase 3 51-84-3 187
45
Doxazosin Approved Phase 3 74191-85-8 3157
46
Finasteride Approved Phase 3,Phase 1,Phase 2,Not Applicable 98319-26-7 57363
47
Prazosin Approved Phase 3,Not Applicable 19216-56-9 4893
48
Norepinephrine Approved Phase 3 51-41-2 439260
49 Antihypertensive Agents Phase 3,Not Applicable
50 Fertility Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy Completed NCT00542165 Phase 4 Alfuzosin
2 A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
3 Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH Completed NCT01260129 Phase 4 Silodosin;Silodosin
4 Effect of Deep BLock on Intraoperative Surgical Conditions Completed NCT01631149 Phase 4 Surgical block (rocuronium; atracurium/mivacurium);Surgical block (rocuronium; atracurium/mivacurium)
5 Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
6 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Completed NCT00752869 Phase 4 dutasteride;placebo
7 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
8 Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms Completed NCT01457573 Phase 4 Tamsulosin;Solifenacin
9 Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair Enrolling by invitation NCT02958878 Phase 4 Tamsulosin;Placebo Oral Capsule
10 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Completed NCT00663858 Phase 3 Cetrorelix 78+78;Cetrorelix 78 + Placebo
11 The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate Completed NCT00427219 Phase 2, Phase 3 Ozarelix/Placebo;Placebo
12 A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy Completed NCT01275521 Phase 3 BONT-A intra-prostatic injection;Optimized medical BPH treatment
13 Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT00670306 Phase 3 Cetrorelix Pamoate
14 Study to Assess the Efficacy of Medi-Tate iTind Device Completed NCT02145208 Phase 3
15 Medical Therapy of Prostatic Symptoms Completed NCT00021814 Phase 3 Doxazosin;Finasteride;Doxazosin placebo;Finasteride placebo
16 Clinical Trial in Males With BPH (Enlarged Prostate) Completed NCT00029822 Phase 3 Alfuzosin (SL770499)
17 "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Completed NCT00056407 Phase 3 Dutasteride;Placebo
18 Combined Behavioral and Drug Treatment of Overactive Bladder in Men Completed NCT01175382 Phase 2, Phase 3 Tolterodine + tamsulosin
19 Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests Recruiting NCT03539614 Phase 3 Prazosin;Placebo
20 Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Terminated NCT00449150 Phase 3 Cetrorelix 78 mg + 78 mg;Cetrorelix 78 mg + 52 mg;Placebo
21 H-36731: Finasteride in Management of Elevated Red Blood Cells Withdrawn NCT02548117 Phase 3 Finasteride
22 A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH). Unknown status NCT00044226 Phase 2 ML-04A
23 Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy Completed NCT00461123 Phase 2 Vardenafil (Levitra, BAY38-9456);Placebo
24 Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT00386009 Phase 2 Tadalafil;Placebo
25 Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
26 A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation Completed NCT00154843 Phase 2 Lycopene
27 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
28 5-Alpha Reductase and Anabolic Effects of Testosterone Completed NCT00475501 Phase 2 Testosterone Enanthate;Finasteride
29 Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH) Recruiting NCT02676544 Phase 1, Phase 2
30 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
31 Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter Recruiting NCT03423979 Phase 2 Paclitaxel
32 Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy Active, not recruiting NCT01446991 Phase 2 Degarelix;Degarelix
33 Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams Terminated NCT02396420 Phase 2
34 Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH) Completed NCT01330927 Phase 1 VA106483
35 A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects Completed NCT02615782 Phase 1 CKD-397
36 Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia Recruiting NCT02592473 Phase 1
37 Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) Unknown status NCT00256399 Not Applicable Alfuzosin 10 mg
38 Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia Unknown status NCT01781117 Not Applicable
39 The Effect of Anterior Corneal Incisions on Intraoperative Floppy Iris Syndrome (IFIS) Incidence and Severity in Tamsulosin Treated Cataract Patients Unknown status NCT01070602 Not Applicable
40 The Effectiveness of 18F-fluorocholine Positron Emission Tomography (PET) in Detecting, Staging and Following-up Prostate Cancer Unknown status NCT01089881
41 Rezum FIM Optimization Unknown status NCT02940392 Not Applicable
42 Rezum I Pilot Study for BPH Unknown status NCT02943070 Not Applicable
43 Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS) Unknown status NCT02024100
44 Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan Completed NCT01323998 5ARI;AB
45 MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer Completed NCT00706966 Not Applicable dutasteride
46 Plasmakinetic Enucleation of the Prostate to Treat Benign Prostatic Hypertrophy Patients With Large Prostate Completed NCT01637701 Not Applicable
47 Safety and Efficacy of OCL 503 in Prostate Artery Embolization Completed NCT02509975 Not Applicable
48 Assessing the Impact of the PVP With Greenlight Laser Using Prostatic MRI and Contrast-enhanced Ultrasound Completed NCT01732991 Not Applicable
49 The Effect of Spermatic Vein Embolization on Prostatic Hypertrophy Completed NCT00639899 Not Applicable
50 Prostate Cancer Antigen 3 (PCA-3) Gene Project Completed NCT01177436 Not Applicable

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Prostatic Hypertrophy

Anatomical Context for Prostatic Hypertrophy

MalaCards organs/tissues related to Prostatic Hypertrophy:

41
Prostate, Kidney, Heart, Bone, Smooth Muscle, Lung, Ovary

Publications for Prostatic Hypertrophy

Articles related to Prostatic Hypertrophy:

(show top 50) (show all 569)
# Title Authors Year
1
Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. ( 29679999 )
2018
2
Investigational procedures in benign prostatic hypertrophy. ( 29528973 )
2018
3
Benign prostatic hypertrophy: PycnogenolAr supplementation improves prostate symptoms and residual bladder volume. ( 29947491 )
2018
4
Silodosin for benign prostatic hypertrophy. ( 30116085 )
2018
5
Drugs for benign prostatic hypertrophy. ( 30410211 )
2018
6
Prostate Artery Embolization for Complete Urinary Outflow Obstruction Due to Benign Prostatic Hypertrophy. ( 27853823 )
2017
7
Investigating the link between benign prostatic hypertrophy, BMI and type 2 diabetes mellitus. ( 28433616 )
2017
8
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway. ( 28332240 )
2017
9
Case-Control Study of Intra-arterial Verapamil for Intraprostatic Anastomoses to Extraprostatic Arteries in Prostatic Artery Embolization for Benign Prostatic Hypertrophy. ( 28506701 )
2017
10
Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies. ( 28593165 )
2017
11
Ageratum conyzoides L. inhibits 5-alpha-reductase gene expression in human prostate cells and reduces symptoms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study. ( 29048765 )
2017
12
The androgen receptor plays different roles in macrophage-induced proliferation in prostate stromal cells between transitional and peripheral zones of benign prostatic hypertrophy. ( 28694768 )
2017
13
Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature. ( 28609136 )
2017
14
Donegal Going against the Flow: National Differences in Long-Term Urinary Catheterisation Rates in Men (> 65 Years) With Benign Prostatic Hypertrophy. ( 29372955 )
2017
15
Re: Stroke Associated with Alpha Blocker Therapy for Benign Prostatic Hypertrophy. ( 27321530 )
2016
16
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with I+-blockers. ( 27629686 )
2016
17
Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5I+-Reductase Associated with Benign Prostatic Hypertrophy. ( 27399661 )
2016
18
Kidney transplant complications from undiagnosed benign prostatic hypertrophy. ( 25832848 )
2015
19
Varicocele: the origin of benign prostatic hypertrophy? Testosterone dosages in the periprostatic plexus. ( 26290288 )
2015
20
The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy. ( 26543428 )
2015
21
Supplementary management of benign prostatic hypertrophy with Prostaquil. An 8-week registry. ( 26492588 )
2015
22
Clinical Outcomes of Transurethral Enucleation with Bipolar for Benign Prostatic Hypertrophy. ( 26662662 )
2015
23
The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function. ( 26438220 )
2015
24
Effects of I+-blocker therapy on active duty military and military retirees for benign prostatic hypertrophy on diabetic complications. ( 25735029 )
2015
25
Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. ( 25587300 )
2014
26
Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis. ( 24754254 )
2014
27
Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy. ( 25348255 )
2014
28
Efficacy of Long-Term Daily Dosage of Alfuzosin 10 mg upon Sexual Function of Benign Prostatic Hypertrophy Patients: Two-Year Prospective Observational Study. ( 25606561 )
2014
29
Re: Editorial comment on constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial: S. A. Kaplan J Urol 2013; 190: 1818-1819. ( 24892642 )
2014
30
Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction. ( 24744521 )
2014
31
Tadalafil and benign prostatic hypertrophy. Too risky. ( 24860894 )
2014
32
Bilateral ureteral obstruction revealing a benign prostatic hypertrophy: a case report and review of the literature. ( 24513237 )
2014
33
Re: a phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. ( 25629105 )
2014
34
Re: Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. ( 24120797 )
2013
35
A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. ( 23642948 )
2013
36
Successful minimally-invasive management of a case of giant prostatic hypertrophy associated with recurrent nephrogenic adenoma of the prostate. ( 23565707 )
2013
37
Alpha-1 adrenergic antagonists in aircrew for the treatment of benign prostatic hypertrophy. ( 23305000 )
2013
38
Correlation of transrectal and transabodominal ultrasound measurement of transition zone volume with post-operative enucleated adenoma volume in benign prostatic hypertrophy. ( 24876907 )
2013
39
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. ( 22123290 )
2012
40
On call. As a retired physician, I particularly appreciate "Harvard Men's Health Watch" since it's an easy way for me to learn about new developments in medicine. As a 78-year-old man with an enlarged prostate, I'm particularly interested in your fine articles about BPH. But if memory serves me right, we called the condition "benign prostatic hypertrophy" when I was in practice, but now you call it "benign prostatic hyperplasia." What's the difference? ( 22670285 )
2012
41
Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. ( 23089217 )
2012
42
The early days of prostatectomy for benign prostatic hypertrophy. ( 22132481 )
2011
43
Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure? ( 21962427 )
2011
44
Sphaeranthus indicus attenuates testosterone induced prostatic hypertrophy in albino rats. ( 21503998 )
2011
45
[Sexual problems in patients with prostate cancer and those with benign prostatic hypertrophy]. ( 21542379 )
2011
46
Analysis of the Pressure-Flow Study in Weak Detrusor Patients with Benign Prostatic Hypertrophy. ( 26676396 )
2011
47
Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy. ( 21221201 )
2010
48
Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. ( 20944533 )
2010
49
Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats. ( 24688153 )
2010
50
Increased frequency and nocturia in a middle aged male may not always be due to Benign Prostatic Hypertrophy (BPH): a case report. ( 19946479 )
2009

Variations for Prostatic Hypertrophy

Expression for Prostatic Hypertrophy

Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for Prostatic Hypertrophy

GO Terms for Prostatic Hypertrophy

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 transcription, DNA-templated GO:0006351 9.72 AR ESR1 PGR
2 transcription initiation from RNA polymerase II promoter GO:0006367 9.67 AR ESR1 PGR
3 positive regulation of protein kinase B signaling GO:0051897 9.65 EGF ESR1 FGF8
4 mammary gland development GO:0030879 9.54 CYP19A1 PGR
5 positive regulation of phosphorylation GO:0042327 9.52 AR EGF
6 positive regulation of mitotic nuclear division GO:0045840 9.51 EGF FGF8
7 phosphatidylinositol phosphorylation GO:0046854 9.5 EGF ESR1 FGF8
8 uterus development GO:0060065 9.46 CYP19A1 ESR1
9 androgen metabolic process GO:0008209 9.43 CYP19A1 ESR1
10 cellular process GO:0009987 9.4 AR TUBB
11 regulation of systemic arterial blood pressure GO:0003073 9.37 AR KLK3
12 steroid hormone mediated signaling pathway GO:0043401 9.33 AR ESR1 PGR
13 prostate gland growth GO:0060736 9.26 AR CYP19A1
14 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 8.96 AR PGR
15 mammary gland alveolus development GO:0060749 8.8 AR EGF ESR1

Molecular functions related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.67 AR ESR1 PCNA PGR
2 ATPase binding GO:0051117 9.5 AR ESR1 PGR
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.43 EGF ESR1 FGF8
4 steroid hormone receptor activity GO:0003707 9.33 AR ESR1 PGR
5 nuclear receptor activity GO:0004879 9.13 AR ESR1 PGR
6 steroid binding GO:0005496 8.8 AR ESR1 PGR

Sources for Prostatic Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....